Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

New COPD treatment approved in Wales

  • Comment

A new treatment for chronic obstructive pulmonary disease has been approved for use by the NHS in Wales.

The All Wales Medicines Strategy Group has recommended aclidinium bromide (Eklira Genuair) as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult COPD patients.

Aclidinium is a new twice-daily, long-acting muscarinic antagonist. It is the first to be delivered by a multi-dose dry powder inhaler.

Evidence considered by the group suggested aclidinium provided noticeable benefits to health-related quality of life and patient symptoms such as breathlessness.

The most frequently reported adverse events in trials were headache and nasopharyngitis.

It is estimated there are 66,951 patients diagnosed with COPD in Wales, according to 2012 data from the GP quality and outcomes framework.

Are you able to Speak Out Safely? Sign our petition to put pressure on your trust to support an open and transparent NHS.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.

Related Jobs